Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade

摘要: Gastric cancer overexpressing the human epidermal growth factor 2 (HER2) protein has a poor outcome, although combination of chemotherapy and anti-HER2 antibody trastuzumab been approved for treatment advanced gastric cancer. Vascular endothelial (VEGF) expression in is correlated with recurrence prognosis; however, anti-VEGF bevacizumab shown limited efficacy against clinical trials. In this study, we evaluated antitumor effects trastuzumab; VEGF-Trap binding to VEGF-A, VEGF-B placental (PlGF); xenograft model. Although each moderately inhibited tumor growth, these agents exerted greater inhibition compared either agent alone. Immunohistochemical analyses indicated that reduction was associated decreased proliferation increased apoptosis cells vascular density. The combined resulted fewer proliferating cells, more apoptotic reduced density or alone, indicating had additive inhibitory on angiogenesis xenografts. These data suggest may represent an effective approach treating HER2-overexpressing